Launch, Value & Access Strategy
How can we build advocacy and prime EU markets for our drug launch in postpartum depression?
A late-stage biopharmaceutical company was preparing for their first CNS product launch in the EU and needed to refine their Medical Affairs strategy to determine which KOL’s were most influential in key strategic markets, and in which capacity their skills would best be leveraged.
Eradigm conducted a systematic and reproducible search of current KOL champions and future rising stars in each market. We then ranked them according to their characteristics and capabilities, providing the client with a future-proofed, prioritised list of individuals in each market to on-board and drive their medical education and pre-launch positioning activities.